Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Natera, Inc.
  6. News
  7. Summary
    NTRA   US6323071042


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Natera, Inc. Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uveal Melanoma

09/17/2021 | 08:33am EDT

Natera, Inc. announced new data being presented by the company and its collaborators on the use of the Signatera® personalized molecular residual disease (MRD) technology at the 2021 European Society for Medical Oncology (ESMO) Congress, taking place September 16–21, 2021. In three new studies, Natera will present the real-world clinical performance of Signatera in esophageal and gastric cancers, the power of ctDNA dynamics for assessing treatment response in uveal melanoma and the correlation of CHIP mutations with patient outcomes. This study used Signatera for the detection and quantification of ctDNA in a prospective real-world cohort of 886 plasma samples from 269 patients with gastroesophageal cancer. Serial time points were collected in a subset of patients to monitor ctDNA levels after curative intent therapy. Analysis showed tumor-informed ctDNA status is highly predictive of relapse in patients with stage I-IV disease, with ctDNA detected in 93.3% of samples at baseline. Uveal melanoma is a rare type of melanoma of the eye, associated with frequent liver metastases. This study of 127 mUM patients used a custom ctDNA assay for the evaluation of tebentasfusp therapy. Baseline ctDNA levels significantly correlated with tumor burden, and by week 9, 70% of evaluable patients showed ctDNA reduction associated with greater mean tumor shrinkage. For tebentafusp, ctDNA reduction appeared more correlated with overall survival than RECIST response. Buffy coat samples derived from 2484 patients diagnosed with colorectal, breast, lung and other solid cancers were analyzed for the presence of CHIP mutations, which were detected in 16% of patients, with the majority having a single mutation. As expected, the frequency of CHIP increased with age and reached 20% in patients above 60 years, who were also more likely to have multiple CHIP variants compared to the younger patients. Although CHIP mutations are not tumor-derived and should not be used to monitor MRD burden, the presence of CHIP in MRD-positive cases was associated with poor patient outcomes and reduced time to recurrence.

© S&P Capital IQ 2021
All news about NATERA, INC.
10/18NATERA : Expands Organ Health Business With Commercial Launch of the Prospera™ Lung ..
10/18Natera, Inc. Expands Organ Health Business With Commercial Launch of the Prospera Lung ..
10/11NATERA : Announces New Publication Validating Signatera® Velocity Metric to Improve Cancer..
10/11Natera, Inc. Announces New Publication Validating Signatera® Velocity Metric to Improve..
10/06INSIDER SELL : Natera
10/06Natera Announces Completion of the Largest Prospective Validation Study of a Commercial..
09/30INSIDER SELL : Natera
09/30VOLPARA HEALTH TECHNOLOGIES : Natera Enter Deal for Supply of Hereditary Cancer Test in US
09/29Volpara Health Technologies Limited to Collaborate with Natera, Inc
09/29NATERA : Court Rules in Natera's Favor Invalidating All of CareDx's Asserted Patents
More news
Analyst Recommendations on NATERA, INC.
More recommendations
Financials (USD)
Sales 2021 615 M - -
Net income 2021 -416 M - -
Net cash 2021 591 M - -
P/E ratio 2021 -24,2x
Yield 2021 -
Capitalization 10 534 M 10 534 M -
EV / Sales 2021 16,2x
EV / Sales 2022 13,5x
Nbr of Employees 1 815
Free-Float 96,3%
Duration : Period :
Natera, Inc. Technical Analysis Chart | NTRA | US6323071042 | MarketScreener
Technical analysis trends NATERA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 10
Last Close Price 112,32 $
Average target price 150,11 $
Spread / Average Target 33,6%
EPS Revisions
Managers and Directors
Stephen Chapman President, Chief Executive Officer & Director
Michael Burkes Brophy Chief Financial Officer
Matthew Rabinowitz Executive Chairman
Paul R. Billings Chief Medical Officer & Senior VP-Medical Affairs
Eric A. Evans Chief Scientific Officer
Sector and Competitors